Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA expedited review and more. In addition, FDA made it quite easy to garner the label. As you can see, there is really no downside to Continue reading Prospecting for New Antibiotics
It has never been easy to cure Pseudomonas aeruginosa infections. Few antibiotics nowadays have reliable activity against this problem pathogen that seems to have more built-in resistance features than most other Gram-negatives. In the past, cephalosporins, aztreonam, penems, ciprofloxacin, and aminoglycosides were useful drugs with reliably cidal activity, especially when Continue reading Fighting P. aeruginosa (Part I)